Treatment with VEGF appeared to ameliorate this defect in autophagy by correcting the sphingolipid abnormalities, indicating that VEGF could be a therapeutic candidate for Niemann-Pick type C disease. This evidence concerns the gene VEGFA and Niemann-Pick disease type C.